Get the Stockscreener App
21.01
1.69%
0.35
After Hours:
21.01
Ascentage Pharma Group International Adr stock is traded at $21.01, with a volume of 8,252.
It is up +1.69% in the last 24 hours and down -16.39% over the past month.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
See More
Previous Close:
$20.66
Open:
$21.4
24h Volume:
8,252
Relative Volume:
2.00
Market Cap:
$1.96B
Revenue:
$80.00M
Net Income/Loss:
$-172.98M
P/E Ratio:
-10.82
EPS:
-1.9419
Net Cash Flow:
$-178.54M
1W Performance:
+7.74%
1M Performance:
-16.39%
6M Performance:
-31.43%
1Y Performance:
-17.80%
1-Day Range:
$20.82
$22.58
1-Week Range:
$18.56
$22.58
52-Week Range:
$18.56
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Name
Ascentage Pharma Group International Adr
Sector
Industry
Phone
-
Address
-
Compare AAPG vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
21.01 | 1.93B | 80.00M | -172.98M | -178.54M | -1.9419 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | Deutsche Bank | Buy |
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Dec-04-25 | Initiated | Oppenheimer | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-10-25 | Initiated | BTIG Research | Buy |
| Nov-05-25 | Initiated | Piper Sandler | Overweight |
| Mar-27-25 | Initiated | JP Morgan | Overweight |
View All
Ascentage Pharma Group International Adr Stock (AAPG) Latest News
AAPG Stock Price, Quote & Chart | ASCENTAGE PHARMA GR-ADR (NASDAQ:AAPG) - ChartMill
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Ascentage Pharma: Buy Rating Reiterated on Advancing CML/ALL Pipeline and DCF-Supported Unchanged $48 Price Target - TipRanks
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail
Ascentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA Congress - TipRanks
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Liquidia Technologies (LQDA) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress - ChartMill
Ascentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor Conferences - TipRanks
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Regeneron (REGN) and Collegium Pharmaceutical (COLL) - The Globe and Mail
AAPG: Ascentage Pharma Group InternationalUnsponsored ADRInteractive Chart - Zacks Investment Research
Analysts Are Bullish on Top Healthcare Stocks: CG Oncology, Inc. (CGON), Evolus (EOLS) - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownTime to Sell? - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Down 51.1% in April - MarketBeat
Analysts’ Top Healthcare Picks: AbbVie (ABBV), Regeneron (REGN) - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's Why - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 8.4%What's Next? - MarketBeat
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO) - The Globe and Mail
Ascentage (AAPG) Stock: Support and Resistance (Momentum Fading) 2026-04-16Momentum Investing - Xã Thanh Hà
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpShould You Buy? - MarketBeat
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Analysts Are Bullish on These Healthcare Stocks: GE Healthcare Technologies Inc (GEHC), Nuvation Bio (NUVB) - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Upgraded at China Intl Cap - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 12%Should You Buy? - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Sahm
Truist Financial Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
BTIG Remains a Buy on Ascentage Pharma Group International Unsponsored ADR (AAPG) - The Globe and Mail
Earnings Scheduled For March 25, 2026 - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 20.3%Should You Buy? - marketbeat.com
Short Interest in Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Increases By 546.9% - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 7.7%Here's Why - MarketBeat
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 - Sahm
Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend - TipRanks
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update - The Globe and Mail
Ascentage Pharma Group International Adr Stock (AAPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):